{"id":"tritanrix-hepb-hib-opv-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine contains inactivated or weakened forms of these pathogens, which are introduced to the body to trigger an immune response. The immune system then produces antibodies to fight these pathogens, providing immunity against future infections.","oneSentence":"Tritanrix-HepB/Hib™ + OPV vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:08.909Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Protection against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus"}]},"trialDetails":[{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT00829010","phase":"PHASE3","title":"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-17","conditions":"Infections, Streptococcal","enrollment":489},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT00514709","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1843},{"nctId":"NCT00313911","phase":"PHASE3","title":"Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":2133},{"nctId":"NCT00343889","phase":"PHASE3","title":"Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-08","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":379},{"nctId":"NCT00534833","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":362},{"nctId":"NCT00348881","phase":"PHASE3","title":"Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":2133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tritanrix-HepB/Hib™ + OPV vaccine","genericName":"Tritanrix-HepB/Hib™ + OPV vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tritanrix-HepB/Hib™ + OPV vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}